Video

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

William D. Tap, MD, medical oncologist, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses developing treatment opportunities in soft tissue sarcomas.

Soft tissue sarcomas represent approximately 80 different diseases, so it is difficult to develop broad treatment approaches, Tap explains. However, the paradigm of soft tissue sarcoma is shifting as nuances within these rare diseases are being better understood.

As such, unique treatment opportunities are being developed internationally for patients with soft tissue sarcomas, Tap says. Broad program project areas are researching drug development and translational medicine to inform how to optimally tailor therapy to individual patients, Tap concludes.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.